Due to mass media enquiries about pharmaceutical benefits for benefit-entitled citizens and the availability of essential drugs in the subjects of the Russian Federation, Roszdravnadzor states the following

Pharmaceutical benefits under the state social assistance program

Overall, the current situation with the medicine supply as part of the state social assistance program can be characterized as stable.

According to health authorities of constituent entities of the Russian Federation, as of 01.07.2017 the medicine shelf inventory capacity funded from the Federal budget resources amounted to 15.9 billion rubles, which is equal to 4.6-month demand based on the average monthly consumption.

The medicine inventory capacity funded from regional budgets’ resources amounted to 28.3 billion rubles, which is equal to 4.3-month demand based on the average monthly consumption.

As part of the Program on State Guarantees to Deliver Free Medical Care to the Citizens of the Russian Federation, the regions formed stocks of medicines amounting to 39.4 billion rubles, which is equal to 3.8-month demand.

As of 03.07.2017 as part of purchasing medicines for patients with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, and for persons after transplantation of organs and (or) tissues, 415,450 prescriptions totaling 24,816,907 thousand rubles were written out and medicines provided in the territory of the Russian Federation.

As part of the RF transferred powers implementation to establish pharmaceutical benefits for certain categories of citizens by government agencies of RF subjects, 23,193,548 prescriptions were written out and medicines provided to the total amount of 31,736,091 thousand rubles.

The share of postponed prescriptions (of the total number submitted to pharmacies and pharmacy organizations) is 0.01%.

Based on the results of Roszdravnadzor control inspections (in the first half-year 2017 – Murmansk, Orlov, Kursk, Vologda and Tver regions), it was noted that the majority of detected problems associated with the medicine supply is of organizational nature.

The most frequently observed ones were the following: shortcomings in the logistics of pharmaceuticals; the lack of a unified information system ensuring the interaction of regional health authorities, medical information-analytical center and medical and pharmaceutical organizations involved in medicine supplies; the prescription support from writing out till the medicine receipt by a patient; insufficient control over inventory management by regional health authorities; as well as low physical availability of drug supply to residents of remote and inaccessible areas, which in some cases leads to the impossibility of providing timely medical assistance to patients.

The monitoring of the range and prices for vital and essential drugs (VED) conducted by Roszdravnadzor

In accordance with the Order of the Health Ministry of Russia No. 277н, pharmacy organizations engaged in drug retail trade and medical organizations involved in their purchase mainly under the territorial programs on state guarantees provide the data for monitoring.

Thus, the monitoring does not provide information on vital and essential drugs purchased under pharmaceutical benefits schemes (first of all, expensive VED) funded from federal and regional budgets’ resources, and as part of pharmaceutical benefits for socially significant diseases – tuberculosis, HIV, etc. (it is a reminder that from 2017 the Ministry of Health of Russia centrally purchases  diagnostic tools and ARV for the identification and treatment of HIV-infected persons and people infected with HIV and hepatitis B and C. The bidding procedures results showed the achievement of financial savings and accomplished deliveries to all regions).

Given the above, Roszdravnadzor believes that the monitoring data cannot serve as the basis for assessing the completeness and quality of pharmaceutical benefits in regions and the availability of specific VED items, since the monitoring does not take into account a full range of medicines required for the provision of pharmaceutical benefits to citizens.

In this regard, the media-spread information that VED reached only 64% of citizens (with reference to Roszdravnadzor monitoring data) does not reflect the real situation in drug supply of the population, formed on the territory of the Russian Federation.